Surgery Websites
T32 Surgical Oncology »  Fellows »  Past Fellows 2020-2021 »  Alexa Glencer, M.D.
Alexa Glencer, M.D.

Alexa Glencer, M.D.

  • Graduate
  • General Surgery Residency Program, 2023

Contact Information

Open Popup

Princeton University - Bachelor's Degree - 2010
University of California San Francisco - Doctor of Medicine - 2016

  • University of California San Francisco Medical Center - General Surgery Intern - 2016-2017
  • University of California San Francisco Medical Center - General Surgery Resident - 2017-present
  • Surgical oncology
  • Hepatobiliary and pancreatic surgery
  • Pancreatic IPMN organoid models of pancreatic cancer
  • Tumor immune microenvironment of DCIS

Alexa Glencer, M.D. is a General Surgery Resident in the UCSF Department of Surgery. Dr. Glencer attended Princeton University as an undergraduate, where she graduated magna cum laude with a major in biology and minors in global health & health policy and environmental science. She then moved to San Francisco, where she worked as a clinical trial coordinator in breast oncology at UCSF before attending medical school. She completed medical school at UCSF, during which time she continued to contribute to breast oncology clinical trial research. During her research years, Dr. Glencer conducted research with Dr. Laura Esserman and Dr. Kim Kirkwood focused on characterizing the tumor immune microenvironment of breast ductal carcinoma in situ (DCIS) and pancreatic intraductal papillary mucinous neoplasms (IPMN). She also worked to develop a novel pancreatic cancer organoid model that she hopes will provide a strong physiologic correlate to the human tumor immune microenvironment.

  • T32 in GI Surgery
MOST RECENT PUBLICATIONS FROM A TOTAL OF 20
Data provided by UCSF Profiles, powered by CTSI
  1. Adam MA, Glencer A, AlMasri S, Winters S, Bahary N, Singhi A, Lee KK, Paniccia A, Zureikat AH. ASO Visual Abstract: Neoadjuvant Therapy Versus Upfront Resection for Non-pancreatic Periampullary Adenocarcinoma. Ann Surg Oncol. 2023 Jan; 30(1):177-178. View in PubMed
  2. Adam MA, AlMasri S, Glencer A, Zureikat AH. Reply to the Letter from Norman G. Nicolson and Jin He on Our Publication "Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma". Ann Surg Oncol. 2022 Dec 07. View in PubMed
  3. Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort. Cancer Res Commun. 2022 12; 2(12):1579-1589. View in PubMed
  4. Adam MA, Glencer A, AlMasri S, Winters S, Bahary N, Singhi A, Lee KK, Paniccia A, Zureikat AH. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma. Ann Surg Oncol. 2022 Aug 04. View in PubMed
  5. Adam MA, Glencer AC, Zureikat AH. ASO Author Reflections: Neoadjuvant Therapy for Nonpancreatic Periampullary Adenocarcinoma. Ann Surg Oncol. 2022 Jul 26. View in PubMed
  6. View All Publications

 

Site Directory
    X